STOCK TITAN

Dermata Therapeutics Inc - DRMAW STOCK NEWS

Welcome to our dedicated news page for Dermata Therapeutics (Ticker: DRMAW), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dermata Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dermata Therapeutics's position in the market.

Rhea-AI Summary
Dermata Therapeutics, Inc. (Nasdaq:DRMA) will provide a corporate update and hold a live Q&A session at the Emerging Growth Conference on April 3, 2024. CEO Gerry Proehl will discuss the company's progress and answer audience questions. The event will be held online, allowing shareholders and investors to interact in real-time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Dermata Therapeutics, Inc. will be featured at the Emerging Growth Conference on February 7, 2024, providing an overview of the Company's business and allowing for audience interaction. CEO Gerry Proehl will answer questions in real time, offering existing shareholders and the investment community valuable insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
conferences acquisition
-
Rhea-AI Summary
Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) has received its first patent in Japan for DMT410, a program using Spongilla technology to deliver botulinum toxin topically for hyperhidrosis. The Japanese prevalence of hyperhidrosis in 2022 was 10%, with approximately 6% having primary axillary hyperhidrosis. The company is currently discussing partnership opportunities to advance the development of DMT410.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
none
Rhea-AI Summary
Tesla Inc. (TSLA) Announces Record-Breaking Q3 Earnings, Surpassing Analyst Expectations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
clinical trial
-
Rhea-AI Summary
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) announces FDA agreement for DMT310 Phase 3 clinical trial protocols, aiming to evaluate the efficacy and safety of once-weekly treatments for moderate-to-severe acne patients. Topline results from STAR-1 clinical trial expected in Q1 2025. DMT310 may be the first once-weekly, topical acne treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
clinical trial
-
Rhea-AI Summary
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) announced a definitive agreement for the immediate exercise of outstanding warrants to purchase up to 3,472,095 shares of common stock at a reduced price of $0.6511 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.75%
Tags
none
Rhea-AI Summary
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) reported $6.8 million in gross proceeds from financings, FDA feedback on Phase 2 meeting package, and start-up activities for DMT310 Phase 3 STAR-1 clinical trial in acne.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.67%
Tags
earnings
-
Rhea-AI Summary
Dermata Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
earnings
Rhea-AI Summary
Dermata Therapeutics announced that its DMT310 Phase 3 clinical development program for the treatment of moderate-to-severe acne is on track to begin in the second half of 2023. The program will consist of two pivotal trials, STAR-1 and STAR-2, and will include additional safety evaluations. The primary endpoints of the trials will be the mean change from baseline in lesion counts and the Investigator Global Assessment response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
clinical trial
Dermata Therapeutics Inc

Nasdaq:DRMAW

DRMAW Rankings

DRMAW Stock Data

5.99M
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
San Diego

About DRMAW

dermata therapeutics, llc is a research company based out of 12340 el camino real, san diego, california, united states.